Earnings date: Thursday, July 30, 2026, before the U.S. market opens; conference call at 8:30 a.m. ET. (investor.regeneron.com)
Regeneron enters 2Q26 with a strong underlying growth engine—principally Dupixent, expanding Libtayo, and continued conversion to EYLEA HD—but with a more complicated earnings setup than the headline revenue trend suggests.
The key debate is whether commercial momentum and a growing set of nearer-term regulatory catalysts can offset:
1. continued erosion in legacy EYLEA,
2. a temporary manufacturing-related gross-margin drag,
3. a disclosed ~$1.00 per-share 2Q hit from acquired IPR&D, and
4. the strategic/perception damage from the failed pivotal fianlimab melanoma trial.
Investors should therefore prioritize the quality and durability of growth, the outlook for 2H26, and management’s credibility on pipeline capital allocation—not simply whether reported EPS clears expectations.
Dupixent is the company’s most important value driver. Global sales reached $4.88 billion in 1Q26, up 33% year over year, while Regeneron recorded $1.45 billion of profit-share revenue from the Sanofi collaboration. The franchise benefits from broad uptake in its core atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis indications, as well as newer launches including COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis. (investor.regeneron.com)
What investors should watch - Whether Dupixent maintains high-20s or better global growth off a much larger base. - U.S. versus international growth, pricing/rebate dynamics, and contribution from newer indications. - Sanofi collaboration profitability—not just sales—because Regeneron participates through its share of collaboration profits. - Commentary on the next-generation immunology portfolio and potential lifecycle-management arrangements with Sanofi.
A notable accounting tailwind is approaching: management said the Sanofi development balance was expected to be fully repaid by the end of 2Q26, with Regeneron’s collaboration revenue expected to reflect its full share of collaboration profits beginning in 3Q26. Thus, the more visible earnings benefit may be a second-half rather than a 2Q event.
The retina franchise remains the key commercial swing factor. In 1Q26, U.S. EYLEA HD sales grew 52% year over year to $468 million, but combined U.S. EYLEA HD plus legacy EYLEA sales fell 10% to $941 million. Importantly, HD sales fell sequentially because of wholesaler-inventory movements even as physician unit demand increased 10% sequentially. (investor.regeneron.com)
Management’s 2Q setup was explicit: - EYLEA HD physician demand was expected to grow sequentially at a rate consistent with 1Q’s 10% growth. - Legacy EYLEA demand was expected to decline in the mid- to high-teens sequentially. - Continued inventory absorption was expected to reduce 2Q legacy EYLEA sales by roughly $20 million.
The read-through: reported franchise sales may still look soft even if EYLEA HD demand is healthy. The most useful datapoints will be HD unit demand, HD’s percentage of franchise sales, net-price trends, biosimilar pressure, and any update on the delayed EYLEA HD prefilled-syringe filing. The FDA had not acted by the prior April action date, and Regeneron had expected a decision on one or both manufacturing-related applications during 2Q.
On July 6, Regeneron pre-announced an approximately $127 million pre-tax acquired IPR&D charge related to upfront and opt-in payments for collaboration and licensing agreements. The company expects the charge to reduce both GAAP and non-GAAP diluted EPS by approximately $1.00 in 2Q26. (investor.regeneron.com)
That makes the quarter unusually sensitive to presentation: - Investors should distinguish operational performance from the IPR&D charge. - Management needs to identify the underlying transactions, strategic rationale, and any future spending commitments. - A clean beat before the charge may not translate into a clean headline EPS outcome.
The charge follows $102 million of IPR&D expense in 1Q26, reinforcing that business development is becoming a more meaningful source of quarterly earnings variability.
First-quarter GAAP product gross margin was just 76%, versus 81% a year earlier, because of a temporary bulk-manufacturing interruption at Regeneron’s Limerick, Ireland facility. The company said initial production resumed in 2Q, but full production was not expected until the end of the quarter; accordingly, GAAP gross margin was expected to remain under pressure in 2Q. (investor.regeneron.com)
Key questions for the call - Has full production normalized on schedule? - Is there any residual inventory write-off, under-absorption, or cost drag extending into 3Q? - Does management maintain its full-year GAAP gross-margin guidance of 77%–78% and non-GAAP guidance of 83%–84%?
A confirmation that the disruption is contained would support the case for improved GAAP margins in the second half. Any delay would be a meaningful negative because it would compound the EYLEA transition issue.
The major negative event since the 1Q call was the Phase 3 failure of fianlimab plus Libtayo in first-line unresectable or metastatic melanoma. The study did not meet its primary progression-free-survival endpoint versus pembrolizumab; high-dose fianlimab plus cemiplimab produced a numerically longer median PFS of 11.5 months versus 6.4 months, but the hazard ratio of 0.845 and p-value of 0.0627 did not reach statistical significance. No new safety signal was identified. (investor.regeneron.com)
This removes what had been an important near-term oncology upside catalyst. The call should clarify: - Whether the ongoing fianlimab-versus-Opdualag melanoma trial remains strategically justified. - The implications for other fianlimab programs, including adjuvant melanoma. - Whether Regeneron changes the expected commercial contribution from fianlimab in its long-range pipeline framing.
Two upcoming regulatory events are more constructive:
Neither is likely to replace the forgone fianlimab opportunity immediately, but positive execution would validate Regeneron’s complement and rare-disease pipeline and create more credible 2027 launch optionality.
For perspective, 2Q25 revenue was $3.68 billion and non-GAAP EPS was $12.89. That quarter included: - Global Dupixent sales of $4.34 billion; - U.S. EYLEA HD sales of $393 million; - Combined U.S. EYLEA franchise sales of $1.15 billion; - Global Libtayo sales of $377 million.
The year-over-year comparison should favor revenue growth from Dupixent, Libtayo, and EYLEA HD, but 2Q26 earnings will face a less favorable mix due to the manufacturing charge and the disclosed IPR&D expense.
REGN’s 2Q26 report is primarily a test of commercial resilience after a pipeline setback. Dupixent should remain the principal source of upside, while EYLEA HD conversion, margin normalization, and the cadence of collaboration-profit recognition will determine whether that growth converts into better second-half earnings power.
The headline EPS result may be noisy because management has already telegraphed a roughly $1.00 per-share IPR&D impact. A constructive report would show continued strong Dupixent growth, healthy EYLEA HD demand despite expected legacy-franchise pressure, confirmation that manufacturing costs are rolling off, and a credible path to pipeline value creation following fianlimab’s failure.